PUBLIC COMPANY
save$BBIOBridgeBio Pharma, Inc.
$BBIO67.25+0.51%Palo Alto, CA, USupdated 1d ago
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 31Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 10, 26SELLKumar Neil· Chief Executive Officer−$1.49M↗
- Apr 10, 26SELLKumar Neil· Chief Executive Officer−$1.49M↗
- Apr 9, 26SELLKumar Neil· Chief Executive Officer−$589K↗
- Apr 9, 26SELLKumar Neil· Chief Executive Officer−$567K↗
- Apr 9, 26SELLKumar Neil· Chief Executive Officer−$530K↗
- Apr 9, 26SELLKumar Neil· Chief Executive Officer−$521K↗
- Apr 9, 26SELLKumar Neil· Chief Executive Officer−$395K↗
- Apr 9, 26SELLKumar Neil· Chief Executive Officer−$382K↗
🐶 Hiring Signal
News
- Mid-cap biotechs join Trump’s latest round of drug pricing dealsFocused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.biopharma_dive · 1mo ago
- FDA green lights Priovant drug for rare skin diseaseLisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.biopharma_dive · 1mo ago
Data sources
last refreshed 32m ago
Found something off?
comments(0)
5-min edit window · permanent after that